Treatment for Bone Metastasis in CRPC - Practical Management for Patient Selection VL

Ensuring Patients Have Access to Radium-223 as a Therapeutic Option: The DORA Trial - Michael Morris

Alicia Morgans, MD, MPH, welcomes Michael Morris, MD, to discuss his recent research into radiopharmaceuticals. The two discuss the DORA trial, which is an international, randomized, phase three study for men who are chemotherapy eligible with metastatic castrate-resistant prostate cancer (mCRPC), who’ve progressed on androgen pathway inhibitors, such as abiraterone or enzalutamide. Biographies: M...

The Importance of Bone-Protecting Agents When Treating mCRPC with Bone Metastatic Disease The PEACE III Trial – Silke Gillessen

In this conversation with Alicia Morgans, Silke Gillessen highlights the bone health analysis evaluating the combination of enzalutamide and radium or enzalutamide alone might affect bone health and fracture rate within patients with metastatic castration-resistant prostate cancer. At the 2021 ASCO meeting, Dr. Gillessen presented an updated safety analysis from the EORTC 1333 / PEACE III trial of...

The Effect of Mandated Bone Protective Agents on Fracture Risk With Longer Follow-Up (EORTC 1333 / PEACE III Trial) – Fred Saad

Bone strengthening agents such as bisphosphonates or the RANKL-targeting antibody denosumab reduced the bone loss associated with androgen deprivation therapy (ADT) and prevent skeletal-related events in castration resistant prostate cancer (CRPC). The use of these agents is recommended in CRPC by many guidelines. The randomized phase III EORTC-1333-GUCG also known as the PEACE-III trial, compares...
email news signup